Sep. 6 at 3:22 PM
While I can appreciate your resolute belief in
$ANVS and Dr. Maccecchini @ILikeDaStocks and the company's statements, past and present ... what I can share with you is that if you are indeed open to a balanced research of the Annovis Bio that you will find discrepancies and out right lies being stated the the CEO.
I am not saying that these were just omissions and/or errors, but that some of her statements ARE lies.
I’ve going to tag
$AVXL since your original post refers to ANVS’ CEO basically saying that her Rx is better than AVXL’s Rx and let AVXL-Longs communicate with you on this matter.
Yes, Dr. Maccecchini believes that her Rx is better than AVXL’s as well as any other on the planet as seen by her response to @ReturnOfEsquire “our drug looks more promising than any Alzheimer drug on the market or in development":
https://stocktwits.com/MaccM/message/606412928
I’m also going to tag Dr. Maria Maccecchini directly via @MaccM because you feel that the “CEO feeling unappreciated for her success thus far, and bit insecure in her role …” referring to your original post.
I don't think, Dr. Maccecchini, is the least bit insecure in any matters running her company.
She has repeated taken the helm as her own CFO again and again and again.
She also believes that she is very, very good at designing drug trials and states this publicly.
She is also so confident that so doesn’t believe she needs a single MD on her team.
She’s basically the perfect package for ANVS-Longs who she hope will go out into the with devotion of spread her gossip. (I am tempted to retract this last sentence, but re-reading your post I don’t think it’s inappropriate and is worthy of reflecting on generically for all investors in this space. Additionally, your post was tagged “Bullish” indicting the likelihood that you were seeking debate as opposed to engagement. Hopefully, AVXL-Longs can provide you the DD supporting their thesis vs. ANVS, which in my opinion should includes factors beyond science alone.)
Whether you believe any of this or not is only “partially" relevant.
I wish I could state that the ONLY thing that mattered are the "entities that specialize in this CNS sector are quite knowledgeable and cautious with their capital. Dr. Maria Maccecchini is over stating her case by continuously making the suggestion that other companies are purposefully closing their eyes to possibilities outside of the amyloid theory and hence missing out on her 900% certain drug."
That quote is from an earlier post of mine:
https://stocktwits.com/ForestFoxes/message/609179296
But I know that Dr. Maccecchini cannot advance her TBI or LBD pipeline. She has at the moment abandoned her pursuit of Parkinson's with the story line that her success with Alzheimer's will save the company (plus, some other excuses about Shorts being means and thoughtless and hating grandparents, etc.)
There is virtually zero prospect that any functional or financially solvent company or entity that specializes in this space will partner with Annovis Bio.
Going forward it's all going to be dilutive AND a full focus by Dr. Maccecchini to induce novice biotech investors and patients to buy her stock.
Her statement published on October 1, 2024, "I will raise money at 30 cents with 100% warrant coverage" is a peek of the future and an affirmation that ONLY Retail money matters to Dr. Maccecchini.
P.S. Dr. Maccecchini was repeatedly made aware in written communications that her statement "Buntanetap is the ONLY drug to attack multiple neurotoxic proteins simultaneously" yet persisted in using her byline despite knowing this fact. If she is so knowledgeable about this space as many ANVS-Long give her credit for, then it is absolutely IMPOSSIBLE for her to have NOT known this lie that she used for years to help sell her stock.
